Raloxifene can reduce risk of a cancer of a mammary gland, especially among women with the family case record.
Raloxifene it was used to prevent back crises among concerning the period after менопаузы women with osteoporosis. It also thought to have some protective effect against a mammary gland cancer, and it has been checked up in MORE (Repeated Results of Estimation Raloxifene) test; it has shown 72 percent reduction of aggressive level of a cancer of a mammary gland after four years of processing, against плацебо. Test has been expanded within even four years, and it has shown that processing of eight years has been connected with 66 percent reduction in risk of a cancer of a mammary gland.

Now researchers at university of Michigan looked at consequences of both tests. It has shown that women both in high and in low risk of a cancer of a mammary gland could be protected raloxifene. Factors of high risk include to be the senior, weighing more norms and having the family case record. Raloxifene reduces risk of a cancer of a mammary gland by 89 percent among women with family history and for 58 percent among who does not have family case record. Not clearly, why the protection given raloxifene, is the biggest among those who is genetically predisposed to a mammary gland cancer, but clearly results are encouraging for these women. Research in raloxifene and as it is compared with тамоксифеном, a standard preparation to reflect a mammary gland cancer, proceeds.

Tags: cancer, Evista, osteoporosis, Raloxifene

This entry was posted on Суббота, Октябрь 3rd, 2009 at 13:43 and is filed under Woman Health. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.